To answer the still unresolved question of the possible leukemogenic effects of extremely low frequency magnetic fields (ELF-MFs) and of their harmonics on the incidence of B acute lymphoblastic leukemia in children, we used an animal model to explore the possible co-initiating or co-promoting effects of ELF-MFs on the development of leukemia. We used a rat model in which B acute lymphoblastic leukemia is chemically induced by a nitrosurea derivative. From the onset of the chemical treatment, the animals were also exposed to ELF-MFs (100 μT, sinusoidal 50 Hz MFs), with or without harmonics. The experiment was conducted on 280 rats. We compared body weight and survival time, percentage of bone marrow blast cells, cumulative incidence of leukemia and type of leukemia in the unexposed groups and in the groups exposed to 50 Hz MFs, with and without harmonics. The results showed no significant differences between exposed and unexposed rats for any of these parameters (p > 0.05). Significant changes in the leukemia type obtained after γ-irradiation of the leukemia model, showed its sensitivity to a physical agent. Our results do not support the hypothesis that ELF-MFs, with or without harmonics, affect the development of B acute lymphoblastic leukemia in children.
INTRODUCTION
Exposure to the 50/60 Hz magnetic fields induced by the production, transport and distribution of electricity is ubiquitous and affects all categories of the population. Since the first epidemiologic study published in 1979, 1) major research efforts, including epidemiologic surveys and in vivo and in vitro biological studies, have focused on the possible adverse health effects that may be associated with these fields. One of the questions still open is whether residential exposure to 50/60 Hz magnetic fields may increase the incidence of Bacute lymphoblastic leukemia (ALL) in children. This is the type most frequently encountered in childhood and accounts for 85% of all childhood leukemia.
In 2001, the International Commission for Non-Ionizing Radiation Protection (ICNIRP) reviewed the voluminous epidemiologic literature on this question of magnetic fields and concluded that childhood leukemia is the disease for which there is the most evidence of an association, at MF exposures above 0.4 μT, with a relative risk of 2.
2) Consideration of this question led the International Agency for Research on Cancer (IARC) to classify magnetic fields in carcinogen category 2b, as "possibly carcinogenic to humans".
3) The basis for this classification is that the epidemiological studies and pooled analyses provide "limited evidence" about carcinogenicity in humans. At the same time, experimental animal data offer "inadequate evidence" of carcinogenicity.
Rigorously conducted animal studies are therefore essential, but a necessary prerequisite is an animal model as close as possible to childhood B-ALL. Until now, animal studies have used models of transplanted leukemia to study the effects of ELF-MFs (extremely low frequency magnetic fields) on the progression phase of the leukemogenic process. [4] [5] [6] But these were not models of lymphoblastic leukemia and they do not allow the possible co-initiating or copromoting effects of electromagnetic fields to be studied in animals.
In this study, we used an animal model of B-ALL, deve-loped in our laboratory, 7) to investigate these effects. Leukemia in this model was chemically induced by a derivative of nitrosourea (n-butylnitrosourea, BNU), reported in the literature to promote leukemogenesis. 8) The animals were exposed to ELF-MFs from the onset of the chemical treatment.
To obtain exposure conditions as realistic as possible, we also considered the potential effects of harmonics, which have never before been investigated in animal studies. WHO guidelines indicate the need to examine any biological effects including on the leukemogenic process of such noise components. 9) For the experiment, animals were exposed to a 50 Hz magnetic field (MFs) of 100 μT, the limit recommended for public exposure by international guidelines. 10) 
MATERIALS AND METHODS

Animals
Eight week-old WKAH/Hkm rats (males and females) were purchased from Japan SLC, Inc. (Hamamatsu, Shizwoka, Japan) for reproduction. New-born males were only used in the experiment, to avoid the mammary tumors previously reported in females after administration of the chemical compound BNU. 8) The experiments started when the rats were three months-old, because the incidence of leukemia is reported to increase up to three months. 8) Each rat was housed in a separate cage and fed a laboratory diet (Safe, Villemoison, France). Rats were housed under wellcontrolled environmental conditions in an animal facility constructed by Charles River-IFFA Credo (L'Arbresle, France). The conditions in this facility were set at standard values and continuously monitored: temperature was regulated at 23-25°C, humidity was always > 50%, light was set at 300 lux, and the dark-light cycle at 18/6 hours (2 pm-8 am). Rats were weighed and observed carefully each time blood was sampled throughout the experiment. Weighing and clinical monitoring increased in frequency (during the final two weeks) when the blood hematological parameters indicated progression of the leukemia process: increased white blood cells, decreased platelets and hemoglobin and the appearance of blast cells in blood. Animals were weighed every two days when the symptoms of the terminal phase of the disease appeared: ruffled fur, slow movements, and difficulty drinking and eating.
All experiments were conducted in accordance with the rules of our institution and with the Council of Europe Guidelines for the care of and experimentation with laboratory animals (Agreement concerning Animal Facility N°A 75-06-02, with the management of the French Veterinary Services, License N° 00840 for experimental studies on living animal issued to Pr J. J Guillosson by the Préfecture de Police de Paris). The work has been submitted for ethical evaluation to the Comité Régional d'Ethique pour l'Expéri-mentation Animale Ile de France, Université René Descartes. It has been approved by the Committee and its registered number is P2.JN.100.08.
Chemicals
The nitrosourea derivative, BNU, was used to initiate the leukemogenic process. It was prepared in our pharmacy according to a previously described procedure.
11) H + RMN (500 MHz) spectral analysis confirmed that the compound was indeed BNU. Its purity and stability over time were verified by microanalysis to an accuracy of ± 0.4%, before the experiments, halfway through them, and after their completion. As BNU is sensitive to light, heat and humidity, it was stored at -20°C until use. A fresh solution was prepared daily. Six mg were dissolved in 0.3 mL ethanol and administered orally to each rat in 15 mL of drinking water, 5 days a week for 24 weeks. Each bottle of BNU was covered with dark paper. On the remaining two days of the week (Saturday and Sunday), water was given ad libitum.
γ-irradiation exposure
To study the sensitivity of our leukemia rat model to the effects of a physical agent, three weeks before treatment with BNU, two groups of 40 rats each were exposed to γ-irradiation from cobalt-60 (ICO 4000 generator). They received 4.8 Gy whole-body irradiation administered in three doses of 1.6 Gy, with a 3-day interval between doses. This dose of 4.8 Gy was chosen because preliminary experiments showed that a higher dose of 6 Gy dramatically reduced the number of platelets in rats. Two other groups of 40 rats each received BNU only and were used as controls.
Experimental design
All experiments were conducted for a period of 52 weeks (Fig. 1) . 280 rats were used in four replicate experiments, with an interval of six weeks between each one. For each experiment, rats were randomly allocated to three groups of 20 rats each and one group of 10, as follows: -20 rats treated with BNU but not exposed to 50-Hz MFs (BNU group); -20 rats treated with BNU and exposed to 50-Hz MFs (BNU + MF group); -20 rats treated with BNU and exposed to 50-Hz MFs with superimposed harmonics (BNU + MF + harm group); -10 rats not treated with BNU and not exposed to 50 Hz MFs were used as the negative controls (No treatment group). For the positive control, another group of 160 rats were used in two replicate experiments, with an interval of 6 weeks. For each experiment, rats were randomly allocated to two groups of 40 rats, as follows: -40 rats were treated with BNU but not exposed to 50-Hz MFs (BNU group) -40 rats were exposed to 4.8 Gy γ-irradiation before treatment with BNU, but not exposed to 50 Hz MFs. BNU treatment started 12 days after γ-irradiation when rats were 3 months old. These rats were used as positive controls (BNU + irrad group).
Sample size was calculated assuming that the one-year cumulative incidence of leukemia was 60% in rats treated with BNU and 80% in rats treated with BNU and exposed to 50 Hz MFs (hazard ratio = 1.7). To provide the study with power > 85% and with a type I error equal to 5%, 80 rats per group were necessary. 12) In addition, 3 sentinel rats were killed at 0, 3, 6, 9 and 12 months to ensure that no bacterial, fungal or viral infections had interfered with the development of leukemia. These controls were performed according to the standards of the Federation of European Laboratory Animal Science Associations (FELASA) at the Department of Medical Microbiology, University Hospital of Nijmegen, Netherlands.
ELF-MF exposure system
All rats were housed in standard plastic cages, in the same room, to avoid differences in their environment. The exposure system, constructed by Electricité de France, is based on the principle of Helmholtz coils and consisted of rectangular coils installed at identical intervals on the shelves where the cages stood (Fig. 2) . The coil design took into account geometrical constrains (size of the rat cages and of the room) and electrotechnical constrains (avoidance of coil vibrations and limitation of the switch-on current). Each coil (60 cm length × 40 cm high) comprised 170, 187 or 196 turns of copper wire (1 mm in diameter), depending on its position in the exposure system. 3D simulations of magnetic fields with EFC400 software (Narda, Germany) verified the homogeneity of the magnetic field in the rat cages and the absence of stray magnetic field over the sham group. This was checked by measurements with MFM10 (Combinova, Sweden) after the exposure system was set up on site. The magnetic field in the middle of the cages varied between 98 μT and 104 μT in the exposed groups. The magnetic field varied between 98 μT and 138 μT in the whole cages and between 98 μT and 123 μT in the space occupied by the animals.
The magnetic field (Fig. 3 ) was generated by a power supply (Chroma, AC model 61601) connected to a computer (Hewlett Packard). The magnetic field and harmonics levels were controlled by probes (Electropreci, France) placed on the shelves and monitored continuously by the computer, using a Labview program (National Instruments, TX). In this study, the 50 Hz exposure level was fixed at 100 μT (timeweighted average: 75 μT). There were no harmonics in the 50 Hz signal.
Rats were exposed to this ELF-MF intensity, 18 h a day (2 pm to 8 am), 7 days a week, throughout the experiment. In the untreated and unexposed group, the magnetic field was 0.035 μT at night and 0.060 μT during the day. The strength of the geomagnetic field in the animal facility was 47 ± 2 μT. The intensity of projection of the horizontal component on the coils was 8 μT. Harmonics were in frequency ranges of 3, 5 and 7 (corresponding respectively to frequencies of 150, 250 and 350 Hz). Harmonic field intensities were 5, 6 and 5 μT respectively.
Temperature and humidity were controlled by air conditioning. The thermal dissipation by Joule effect was estimated at 355 mV by cage in the exposed group.
Leukemia detection
Cytological examination, cytochemical testing for esterase and peroxidase reactions, and immunophenotyping with specific antibodies of blast cells enabled us to define the characteristics of the leukemia induced by BNU.
To measure the hematological parameters, blood samples were obtained by puncture of the retro-orbital plexus. For this purpose, rats were anesthetized with isoflurane in a veterinary gas evaporator (Minerve, Esternay, France). Blood samples of 0.2 mL were collected, first monthly, then twice monthly, in 1.3 mL plastic tubes containing heparin (Sarstedt, Orsay, France). The following parameters were evaluated regularly with an automatic veterinary counter (ABX minos Vet, ABX, Montpellier, France): white and red blood cell counts, platelets counts, hemoglobin level, hematocrit, mean cell volume, and mean cell hemoglobin concentration. Differential blood cell counts were performed on smears stained with May-Grünwald Giemsa (MGG). Two hundred cells per sample were examined.
When leukemic rats appeared so ill clinically that they would not survive for one more day, they were killed by an intraperitoneal injection of 1 mL of 6% pentobarbital (Centravet, Dinan, France). The clinical characteristics used to evaluate the progression of leukemia were ruffled fur, slow movements, drinking and eating with difficulty, loss of body weight in a few days. Rats were weighted every two days at the time of blood puncture, and then every day when symptoms of disease appeared. Laboratory indicators such as thrombopenia, anemia and the appearance of blast cells in the peripheral blood were associated with the development of leukemia. After rats were killed, peripheral blood and bone marrow cells were collected to measure hematological parameters, differential counts of blood and bone marrow cells, cytochemical test reactions, and immunologic labeling. The remaining cells were frozen.
Characterization of leukemia
All analyses were conducted in a blinded manner, and the operator was not aware of the code number attributed to each rat. To identify the leukemia phenotype, blood and bone marrow cells from leukemic rats underwent cytological examination, and their cytochemical reactions were tested. For these purposes, cytospins were prepared with bone marrow cells obtained from both femurs of each rat. Cytospins were either stained with MGG for cytological examination or used to test cytochemical reactions for the presence of both esterase (with or without Na-fluoride) to detect leukemic cells of the monocytic lineage 13) and peroxidase for the detection of leukemic cells of the granulocytic lineage. 14) Immunophenotyping was performed on 2 × 10 6 bone marrow cells. Cells were washed twice in PBS and incubated for 30 min with either FITC-labeled or purified antibodies, whose fixation was revealed with an FITC secondary antibody. To reveal intracellular antigens, cells were fixed and permeabilized with Fix and Perm permeabilization kits (Caltag Laboratories, Tebu, Le Perray en Yvelines, France), washed in PBS and incubated with the various antibodies used. After labeling, the cell preparations used to reveal intracytoplasmic or surface markers were fixed in PBS containing 1% formaldehyde solution (VWR, Fontenay sous Bois, France). Labeled cells were examined and analyzed with an XL Coulter FACS (Beckman Coulter, Villepinte, France) and Cell Quest software.
All the antibodies used, except those directed against the immunoglobulin light chain λ, were directly labeled with FITC. For B-cell identification, we used goat polyclonal antibody directed against the immunoglobulin heavy chain μ (Rockland, TEBU-BIO, France) and mouse monoclonal antibodies directed against the immunoglobulin light chains κ and λ (Cederlane and Caltag Laboratories, respectively). For T-cell identification, we used mouse monoclonal antibodies directed against the T cell receptor chains αβ and γδ (Cederlane) and against the Pan T lymphocyte antigen (Cederlane). Cells were also labeled with mouse monoclonal antibodies directed against the CD90 (Thy-1) antigen, a marker for hematopoietic stem cells and immature B cells (Caltag Laboratories). The fluorescence of each antibody was determined with its corresponding monoclonal IgG1, IgG2a or IgG2b isotype (Caltag Laboratories) or its corresponding polyclonal IgG isotype (Rockland).
Statistical analysis
Survival time and cumulative incidence of leukemia for each group of rats were derived from Kaplan-Meier estimates. Rats without leukemia which were dead by 52 weeks were censored at the final follow up for the cumulative incidence of leukemia. For the cumulative incidence, the groups were compared with Cox regression analysis to adjust for each experiment. Survival curves were compared with LogRank analysis. Blood and bone marrow hematological indicators were tested with one-way analysis of variance, with blocks including the experiment number. The values for each experiment were pooled and the mean value was calculated for the four replications. Fisher's exact test was used to compare the types of leukemia observed in each group. Analyses of variance compared weight loss and blast cell invasion. All analyses were performed with the SAS software package V8.2 (SAS Institute, Cary, NC).
RESULTS
Body weight
As body loss was observed at the end of leukemia development, it was the first characteristic we compared in the treated groups. Rats lost 11 ± 8% of body weight in the BNU-, 15 ± 11% in the BNU + MF-, 12 ± 9% in the BNU + MF + harm-treated groups and 12 ± 8% in the BNU + irradiated group. No significant difference in weight loss was observed between these groups (p = 0.23). Figure 4 represents the average body weight of rats treated with BNU alone and of those exposed to ELF-MFs (with or without harmonics) or exposed to γ-irradiation. 
Characterization of induced leukemia
Blood parameters, measured when rats were killed, are shown in Table 1 for control rats (no treatment) and for rats that developed ALL in the BNU-treated group, in the BNUtreated groups exposed to ELF-MFs, with or without harmonics and in the BNU-treated group exposed to γ-irradiation. In the terminal phase of leukemia progression, white blood cell counts rose dramatically. Anemia, reflected by decreases in hemoglobin, hematocrit and red cell counts, and thrombopenia (decreased platelet count) were also detected. Differential blood cell counts revealed the presence of blast cells in the peripheral blood of all rats that developed ALL. Erythroid precursors were detected in the peripheral blood of rats with erythroleukemia (10 rats in each of the BNU, BNU + MF, and BNU + MF + harm groups). In contrast, no leukemia of the erythroid lineage (erythroleukemia) occurred in the BNU + irrad group (positive control). Blasts of the monocytic series were identified in the few cases of acute monocytic leukemia, blasts of the granulocytic series in one case of acute myeloblastic leukemia (BNU + MF group), and myeloid precursors in the only case of myeloproliferative disorder (BNU + MF + harm group).
Differential bone marrow cell counts were performed when the rats were killed to determine the percentage of blast cells. Leukemia was classified as acute when the bone marrow contained more than 20% blast cells. Differential bone marrow cell counts for rats developing B-ALL in the four treatment groups (BNU, BNU + 50Hz, BNU + 50Hz + harm, BNU + irrad) are shown in Table 2 . No significant differences were found between these four groups for the percentages of blast cells in the bone marrow of leukemic rats (p = 0.95). In the untreated group, the proportion of blast cells never exceeded 0.5%.
To characterize blast cells, cytochemical reactions were tested on bone marrow cytospins to reveal the presence of myeloperoxidase and esterase. The results showed negative results in blast cells except in a few rats: a strong positive esterase reaction, totally inhibited with Na-fluoride, corresponding to the phenotype of acute monocytic leukemia, was found in leukemic cells in a few cases (2 in the BNU group, 4 in the BNU + MF group, 1 in the BNU + MF + harm group and 5 in the BNU + irrad group). A strongly positive peroxidase reaction was observed in the only case of myeloproliferative disorder, mentioned above, in a rat in the BNU + MF + harm group, and in the only case of acute myeloid leukemia, in the BNU + MF group. To characterize leukemia more precisely, immunophenotyping was performed on bone marrow cells of all rats, including healthy Table 2 . Differential bone marrow cell counts in untreated rats and rats with acute lymphoblastic leukemia in the treated groups.
Cell type (%)
No treatment • Untreated rats not exposed to 50 Hz MFs. ■ BNU-treated rats not exposed to 50 Hz MFs. □ BNU-treated rats exposed to 50 Hz MFs. ◇ BNU-treated rats exposed to 50 Hz MFs with superimposed harmonics. ○ BNU treated rats exposed to γ-irradiation. BNU: Butylnitrosourea, MFs: magnetic fields.
controls. The results are shown in Table 3 . Blast cells that showed positive labeling for CD90 only (Thy-1) were classified as immature leukemic cells. When blast cells exhibited the immunoglobulin heavy chain μ, at least in the cytoplasm, the leukemia was classified as B-ALL (pre-B subtype). As shown in Table 3 , the expression of the immunoglobulin heavy chain in these leukemic cells was associated in most cases with expression of the CD90 (Thy-1) marker. The heavy chain μ was detected mainly in the intracellular compartment. Low extracellular levels of this heavy chain, as well as low levels of the extra-or intracellular light chains κ and λ, were very occasionally detected in blast cells. The total absence of blast cells with the T-cell receptor αβ or γδ chains indicated that no leukemia of the T-cell lineage was present. We therefore separated acute leukemia with negative cytochemical reactions into two types: immature leukemia expressing CD90 only and B-ALL (pre-B subtype) expressing the immunoglobulin heavy chain μ associated or not to CD90.
Incidence of leukemia
At the end of the experiments, we compared the percentages of total leukemia and of each type of leukemia in the treated groups (Table 4) . Throughout the entire course of the experiment, we detected no cases of spontaneous leukemia and no modification of hematological indicators in the untreated rats (those not given BNU and not exposed to 50 Hz MFs). These rats were killed at the end of the experiment, i.e., at 52 weeks. In addition to leukemia, BNU induced tumors and aplasia in other rats before the end of the experiment. These rats were also killed during the experiment.
Leukemia was induced in 60% of the rats in the BNU group, 60% of the BNU + MF group, 69% of the BNU + MF + harm group and 59% of the BNU + irrad group (Table  4) . No significant difference was found between these groups in the total number of leukemia (p > 0.5). As reported in our model [7] , the leukemia cases induced were mostly of the B-ALL phenotype (pre-B subtype). The nonlymphoid types of leukemia were mainly erythroleukemia and, to a lesser extent, immature leukemia. No significant difference between groups was found in the distributions of the types of leukemia (p = 0.51), except for the BNU + irrad group (positive control) in which no leukemia of the erythroid lineage (erythroleukemia) was detected (Table 4) . Thus, the percentage of erythroleukemia in the BNU and in the BNU + irrad groups differed significantly (p = 0.001). In addition, the number of combined cases of ALL and immature leukemia was significantly higher in the irradiated group than in the group treated with BNU alone (p = 0.043). The leukemia cell type classified as immature leukemia was identified by a negative reaction for peroxidase and for 
Pan T (%) 2.5 ± 1 2.9 ± 0.9 2.3 ± 0.6 3.5 ± 1.8 3.1 ± 1.5 
TCRαβ (%) 2.7 ± 2.6 2.9 ± 1.1 2.3 ± 0.7 5.6 ± 2.4 3.0 ± 2.2 TCRγδ (%) 0.6 ± 0.5 0.4 ± 0.2 0.7 ± 0.2 1 ± 0.1 0.5 ± 0.3 a mean ± SD.
• Untreated rats not exposed to 50 Hz MFs. ■ BNU-treated rats not exposed to 50 Hz MFs. □ BNU-treated rats exposed to 50 Hz MFs. ◇ BNU-treated rats exposed to 50 Hz MFs with superimposed harmonics. ○ BNU-treated rats exposed to γ-irradiation. BNU: Butylnitrosourea, MFs: magnetic fields. • Untreated rats not exposed to 50 Hz MFs. ■ BNU-treated rats not exposed to 50 Hz MFs. □ BNU-treated rats exposed to 50 Hz MFs. ◇ BNU-treated rats exposed to 50 Hz MFs with superimposed harmonics. ○ BNU treated rats exposed to γ-irradiation. ✹ control for BNU + Irrad. Others: Acute monocytic leukemia, myeloproliferative disorder, acute myeloid leukemia. BNU: Butylnitrosourea, MFs: magnetic fields.
esterase and the presence of the marker CD 90. As pointed out above, these are characteristics common to undifferentiated leukemia and to the most immature B-ALL. Therefore, we can assume that immature leukemia may involve a number of ALL cells that we cannot identify precisely since the marker for acute lymphoblastic leukemia more immature than pre-B ALL (CD10) was not available for immunophenotyping in rats as in humans. The cytological examination of the immature leukemic cells in the bone marrow showed that these immature leukemia cells appeared mostly as possibly leukemic cells of the B cell lineage. Comparison of the survival time (Fig. 5 ) for all rats in the four treated groups (BNU, BNU + MF, BNU + MF + Harm, BNU + irrad) showed no significant differences (p = 0.17).
The determination of cumulative incidence of leukemia took into account the rats that were killed for causes other than leukemia. In the treated groups, the cumulative incidence of leukemia was 83% (standard error (SE): 0.09) in the BNU group, 79% (SE: 0.06) in the BNU + MF group and 91% (SE: 0.06) in the BNU + MF + harm group (Fig. 6 ). In the BNU + irrad group (positive control), the cumulative incidence of leukemia was 86% (SE: 0.12). Note that these values were obtained between weeks 41 and 44 of the experiments, as only rats in the BNU + MF + harm group survived through 52 weeks. The rats in the no treatment group were kept under observation throughout the experiments.
The relative risk of developing leukemia was investigated in the different treatment groups. In most rats with leukemia, In the BNU + irrad group (positive control), the global risk of developing any leukemia was similar to that of the BNU group [RR: 1.22 (95% CI = 0.7-2.13, p = 0.46]. As mentioned above, however, the type of leukemia obtained after treatment with the leukemic agent differed significantly between these two groups mentioned above (BNU alone and BNU + irrad.).
The results obtained in the sentinels enabled us to verify that no bacterial or fungal infection was detected during the experiment. In addition, no pathogenic virus was identified, in particular no virus that could influence a leukemogenic process, such as the Sendai virus, which can induce immunodeficiency.
DISCUSSION
The objective of the present study was to use a rat model of acute leukemia to determine whether ELF-MF exposure has co-initiating or co-promoting effects on leukemia development, particularly B-ALL, the most frequent type of childhood leukemia. Our animal model of B-ALL is the first to assess the possible leukemogenic effects of ELF-MFs. The transplanted leukemia models that have been used in other animal studies [4] [5] [6] cannot assess such leukemogenic effects from the initiation through the progression phases. Our model corresponds to the pre-B subtype of ALL in humans, which accounts for 25 to 30% of childhood leukemias, according to the ALL classifications. 15, 16) In this subtype, postnatal translocations, such as t(1;19), have been observed, 17) in contrast to other subtypes (Common and pro-B) where most translocations are of prenatal origin, 18, 19) including for example, t(12;21) and t(4;11). These translocations were not found in all cases. Only 20 to 25% of the Common subtype had the t(12;21) translocation, the most frequently encountered translocation in ALL. This suggests that other genetic events or risk factors, which remain to be discovered, may be involved in the B-ALL process.
Comparison of the group treated with BNU but not exposed to 50 Hz MFs with the group exposed to 50 Hz MFs showed no significant differences for invasion of bone marrow cells, survival time, and cumulative incidence or type of leukemia. Furthermore, the addition of superimposed harmonics, to investigate 50-Hz MF effects under more realistic conditions, did not modify these variables. This is the first time that the potential adverse effects of harmonics on cancer end points have been investigated. One team examined the possible effects of harmonics on the night-time secretion of melatonin, cortisol, growth hormone and prolactin in humans and observed no effects. 20) In our experiments, a group of rats pre-irradiated by γ-rayirradiation before BNU treatment (BNU + irrad group) was used as positive control. The γ-irradiation induced a significant change in the leukemogenic process induced by BNU, a leukemic agent. In contrast to the rats treated with BNU alone, no leukemia of the erythroid series (erythroleukemia) occurred in the irradiated rats. The absence of erythroleukemia induction in the BNU + irrad group might be due to the higher sensitivity of erythroid progenitors injured by γ-irradiation, as previously reported 21) or to the induction of genetic events that induces changes in the clonal proliferation of hematopoietic progenitor cells. Furthermore, the number of cases of ALL and immature leukemia combined was significantly higher in the irradiated group than in that treated with BNU alone (p = 0.043). This was confirmed in two replicates with 40 rats each. The significant changes in the leukemia cell types obtained in the irradiated group makes it possible to think that a physical agent can modulate our model. Our experiment showed no such combined decrease in erythroleukemia and increase in immature leukemia (involving undifferentiated leukemia and the most immature ALL) in rats treated with BNU and exposed to ELF-MFs, with or without harmonics.
Our results are consistent with those of other in vivo investigations of the effects of ELF-MFs on the progression of transplanted leukemia. They also corroborate the findings of Mandeville, 22) who reported that ELF-MFs did not significantly affect the incidence of spontaneous mononuclear cell leukemia in Fischer rats exposed to ELF-MFs for 2 years. In other animal studies who investigated the effects of ELF-MFs on the incidence of lymphoma similarly negative results were reported. In three reports, T-cell lineage lymphomas were induced in mice, either by dimethylbenzanthracene administration 23) or by Eμ-pim1 transgenesis. 24, 25) In another model of spontaneous T-lymphoma in genetically predisposed mice, 26, 27) Sommer found any ELF-MF effect on the incidence of such hematopoietic malignancy.
Most animal studies investigating the possible carcinogenic effects of ELF-MFs with various cancer models (rat liver, mouse skin, rat brain and rat mammary gland) have also obtained negative results. Only for mammary carcinoma have discordant results been reported: they vary according to the substrain of rat used. 28) In vitro studies of hematopoietic cells designed to identify possible mechanisms by which ELF-MFs might have effects at the cellular level also reported negative results. Thus, investigations of the proliferation, clonogenicity or cell cycle kinetics of mouse multipotential hematopoietic progenitors 29) or purified human multipotential CD34 + hematopoietic progenitors 30) revealed no effects. One team has reported a 10% reduction in the proliferation and differentiation of mouse granulocytic-macrophage progenitors (CFU-GM) when bone marrow cells were exposed to 80 μT ELFMFs.
31)
The only positive effects of ELF-MFs reported in the literature were an enhancement of the mutagenic effects induced by genotoxic agents. Thus, an increase of γ-ray or X-ray-induced mutation frequencies in the HPRT gene of CHO and MO54 cell lines 32, 33) or in the sup F gene carried by pTN89 plasmids in Escherichia coli 34) was observed after ELF-MF exposure. In addition, an increase in UV-induced gene conversion rate was obtained in a DNA repairproficient yeast strain. 35) However, we can notice that these genotoxic effects were obtained with much more stronger ELF-MFs levels of intensity (ranging from 700 μT to 30 mT) than that used in our study (100 μT).
In conclusion, this is the first time, as far as we know, that an animal model of B-ALL has been used to investigate the possible leukemogenic effects of 50-Hz MFs. It is also the only investigation to date of the possible leukemogenic effects of the harmonics that may be involved in any adverse effects of ELF-MFs on health. Under our experimental conditions, neither 50-Hz MFs nor 50-Hz MFs with superimposed harmonics affected any of the indicators involved in the development of B-ALL in our animal model. They are in agreement with the results of epidemiological studies performed on a large number of leukemia cases and for which magnetic fields measurements are reported. [36] [37] [38] [39] In contrast, our findings do not corroborate the results of the pooled analyses published in 2000 2) which showed an association between the risk of childhood leukemia and residential ELF-MF exposures above 0.4 μT. The discrepancy between epidemiological and experimental research may be due to methodological limitations. Indeed, it would be of interest to take into account the other environmental risk factors such as traffic air pollutants: benzene and NO2, 40, 41) industrially related emissions of volatile organic compounds: 1,3-butadiene, dioxins and ben(a)-pyrene, 42) pesticides, insecticides 43, 44) and ionizing radiations (in utero and post natal exposures), possibly involved in childhood leukemia. 45) An unusual pattern of exposure to viral infections, possibly linked to population mixing, was also reported as another risk factor for childhood leukemia. 46) Further epidemiologic and experimental studies are required to understand the implication of the various risk factors for childhood leukemia which may stem from a combination of genetic susceptibility and environmental and/or infectious exposures.
